Veru to Present at the GLP-1 Based Therapeutics Summit
May 02, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
May 01, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
April 30, 2024 08:30 ET
|
Veru Inc.
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30,...
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
April 25, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Announces Date of 2024 Annual Meeting of Shareholders
April 01, 2024 16:05 ET
|
Veru Inc.
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late...
Veru Reschedules Annual Meeting of Shareholders
March 22, 2024 16:05 ET
|
Veru Inc.
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22,...
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
March 12, 2024 08:00 ET
|
Veru Inc.
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality...
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
February 27, 2024 19:15 ET
|
Veru Inc.
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher...
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
February 20, 2024 08:30 ET
|
Veru Inc.
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality...
Veru Reports Fiscal 2024 First Quarter Financial Highlights
February 08, 2024 06:30 ET
|
Veru Inc.
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone— —Company to...